QQQ   293.30 (-0.02%)
AAPL   147.81 (-0.15%)
MSFT   254.17 (-0.38%)
META   120.29 (+1.85%)
GOOGL   101.19 (+0.20%)
AMZN   96.05 (-0.51%)
TSLA   194.71 (+0.01%)
NVDA   171.08 (+1.09%)
NIO   12.32 (-3.60%)
BABA   86.41 (-1.31%)
AMD   77.00 (-0.81%)
T   19.13 (-0.78%)
MU   55.81 (-3.19%)
CGC   3.69 (+1.93%)
F   14.14 (+1.73%)
GE   85.85 (-0.14%)
DIS   98.03 (+0.16%)
AMC   8.41 (+16.32%)
PYPL   78.44 (+0.04%)
PFE   50.75 (+1.24%)
NFLX   317.01 (+3.76%)
QQQ   293.30 (-0.02%)
AAPL   147.81 (-0.15%)
MSFT   254.17 (-0.38%)
META   120.29 (+1.85%)
GOOGL   101.19 (+0.20%)
AMZN   96.05 (-0.51%)
TSLA   194.71 (+0.01%)
NVDA   171.08 (+1.09%)
NIO   12.32 (-3.60%)
BABA   86.41 (-1.31%)
AMD   77.00 (-0.81%)
T   19.13 (-0.78%)
MU   55.81 (-3.19%)
CGC   3.69 (+1.93%)
F   14.14 (+1.73%)
GE   85.85 (-0.14%)
DIS   98.03 (+0.16%)
AMC   8.41 (+16.32%)
PYPL   78.44 (+0.04%)
PFE   50.75 (+1.24%)
NFLX   317.01 (+3.76%)
QQQ   293.30 (-0.02%)
AAPL   147.81 (-0.15%)
MSFT   254.17 (-0.38%)
META   120.29 (+1.85%)
GOOGL   101.19 (+0.20%)
AMZN   96.05 (-0.51%)
TSLA   194.71 (+0.01%)
NVDA   171.08 (+1.09%)
NIO   12.32 (-3.60%)
BABA   86.41 (-1.31%)
AMD   77.00 (-0.81%)
T   19.13 (-0.78%)
MU   55.81 (-3.19%)
CGC   3.69 (+1.93%)
F   14.14 (+1.73%)
GE   85.85 (-0.14%)
DIS   98.03 (+0.16%)
AMC   8.41 (+16.32%)
PYPL   78.44 (+0.04%)
PFE   50.75 (+1.24%)
NFLX   317.01 (+3.76%)
QQQ   293.30 (-0.02%)
AAPL   147.81 (-0.15%)
MSFT   254.17 (-0.38%)
META   120.29 (+1.85%)
GOOGL   101.19 (+0.20%)
AMZN   96.05 (-0.51%)
TSLA   194.71 (+0.01%)
NVDA   171.08 (+1.09%)
NIO   12.32 (-3.60%)
BABA   86.41 (-1.31%)
AMD   77.00 (-0.81%)
T   19.13 (-0.78%)
MU   55.81 (-3.19%)
CGC   3.69 (+1.93%)
F   14.14 (+1.73%)
GE   85.85 (-0.14%)
DIS   98.03 (+0.16%)
AMC   8.41 (+16.32%)
PYPL   78.44 (+0.04%)
PFE   50.75 (+1.24%)
NFLX   317.01 (+3.76%)
NASDAQ:TTNP

Titan Pharmaceuticals - TTNP Stock Forecast, Price & News

$0.88
+0.07 (+8.20%)
(As of 12/1/2022 11:34 AM ET)
Add
Compare
Today's Range
$0.85
$0.88
50-Day Range
$0.81
$1.14
52-Week Range
$0.35
$1.59
Volume
135 shs
Average Volume
20,445 shs
Market Capitalization
$12.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TTNP stock logo

About Titan Pharmaceuticals (NASDAQ:TTNP) Stock

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Stock News Headlines

Titan Pharmaceuticals Raises $5.5M Via Equity
Titan Pharmaceuticals to Explore Strategic Alternatives
See More Headlines
Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Company Calendar

Last Earnings
3/30/2021
Today
12/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTNP
Employees
11
Year Founded
N/A

Profitability

Net Income
$-8,780,000.00
Net Margins
-1,779.72%
Pretax Margin
-1,779.72%

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
$0.24 per share

Miscellaneous

Free Float
14,234,000
Market Cap
$12.85 million
Optionable
Optionable
Beta
1.08

Key Executives

  • Dr. Katherine L. Beebe-DeVarney Ph.D. (Age 61)
    Pres, COO & Director
    Comp: $383.64k
  • Dr. Marc Rubin M.D. (Age 67)
    Exec. Director
    Comp: $390.24k
  • Mr. David Elliot Lazar (Age 31)
    Principal Exec. Officer, Principal Financial Officer, CEO & Interim Chairman
  • Mr. Mike Fritz
    National Sales Director
  • Jennifer Kiernan
    Exec. Assistant to CEO & Investor Communications Coordinator
  • Joe Schrei
    Exec. Director of Commercial Operations













TTNP Stock - Frequently Asked Questions

Should I buy or sell Titan Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTNP, but not buy additional shares or sell existing shares.
View TTNP analyst ratings
or view top-rated stocks.

How have TTNP shares performed in 2022?

Titan Pharmaceuticals' stock was trading at $1.02 at the beginning of 2022. Since then, TTNP shares have decreased by 20.4% and is now trading at $0.8120.
View the best growth stocks for 2022 here
.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings data on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 1,779.72% and a negative trailing twelve-month return on equity of 183.12%.

When did Titan Pharmaceuticals' stock split?

Shares of Titan Pharmaceuticals reverse split on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?
What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Truist Financial Corp (4.27%), Renaissance Technologies LLC (0.99%), State Street Corp (0.26%), Virtu Financial LLC (0.19%), FNY Investment Advisers LLC (0.19%) and Group One Trading L.P. (0.00%).
View institutional ownership trends
.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $0.81.

How much money does Titan Pharmaceuticals make?

Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $11.88 million and generates $1.53 million in revenue each year.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956.

This page (NASDAQ:TTNP) was last updated on 12/1/2022 by MarketBeat.com Staff